Skip to main content

Fragile X Syndrome clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for
  • Metformin in Individuals With Fragile X Syndrome

    “Learn if Metformin may be helpful for language, behavior problems, and obesity / excessive appetite in patients with Fragile X Syndrome.”

    open to eligible people ages 6-25

    This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.

    Sacramento, California and other locations

  • Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

    “Children and teens between 3 and 17 diagnosed with Fragile X syndrome may qualify for a clinical trial”

    open to eligible people ages 3-23

    This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to < 23 years will be eligible to participate.

    Sacramento, California and other locations

Our lead scientists for Fragile X Syndrome research studies include .